The US Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an investigational therapy for the treatment of generalised myasthenia gravis (gMG).  CNP-106 is a biodegradable nanoparticle that encapsulates seven acetylcholine receptor (AChR) antigens. It is being evaluated for its potential to induce antigen-specific immune tolerance in anti-AChR antibody positive generalised MG, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!